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A B S T R A C T
Müller glia are responsible for the neural retina regeneration observed in ﬁsh and amphibians throughout life.
Despite the presence of these cells in the adult human retina, there is no evidence of regeneration occurring in
humans following disease or injury. It may be possible that factors present in the degenerated retina could
prevent human Müller glia from proliferating and neurally diﬀerentiating within the diseased retina. On this
basis, investigations into the proteomic proﬁle of these cells and the abundance of key proteins associated to
Müller glia in the gliotic PVR retina, may assist in the identiﬁcation of factors with the potential to control Müller
proliferation and neural diﬀerentiation in vivo. Label free mass spectrometry identiﬁed 1527 proteins in Müller
glial cell preparations, 1631 proteins in normal retina and 1074 in gliotic PVR retina. Compared to normal
retina, 28 proteins were upregulated and 196 proteins downregulated by 2-fold or more in the gliotic PVR retina.
As determined by comparative proteomic analyses, of the proteins highly upregulated in the gliotic PVR retina,
the most highly abundant proteins in Müller cell lysates included vimentin, GFAP, polyubiquitin and HSP90a.
The observations that proteins highly upregulated in the gliotic retina constitute major proteins expressed by
Müller glia provide the basis for further studies into mechanisms that regulate their production. In addition
investigations aimed at controlling the expression of these proteins may aid in the identiﬁcation of factors that
could potentially promote endogenous regeneration of the adult human retina after disease or injury.
1. Introduction
A common characteristic of retinal degeneration is reactive gliosis, a
term coined to describe a process where Müller glia rapidly proliferate
(Dyer and Cepko, 2000), undergo morphological changes (Lewis and
Fisher, 2003), and release pro-inﬂammatory and regulatory factors into
the local retinal environment (Bringmann et al., 2009). This process,
thought to protect the retina from further damage, is not always ben-
eﬁcial and can lead to the formation of glial scarring which further
aggravates retinal degeneration (Bringmann and Wiedemann, 2012). As
Müller cell gliosis is the main characteristic of retinal degenerative
disorders (Fariss et al., 2000; Graf et al., 1993; Rungger-Brandle et al.,
2000; Wu et al., 2003), a greater understanding of the molecular events
that occur in this process is required to develop therapeutic strategies to
promote self-repair and consequently endogenous regeneration.
Müller glia provide structural and homeostatic support to retinal
neurons and constitute the ﬁrst line of reactivity upon retinal damage.
Whilst Müller glia are responsible for the regeneration observed in
zebraﬁsh retina after injury, there is no evidence that these cells have
regenerative ability in humans. On the contrary, Müller cells are known
to undergo changes which lead to reactive gliosis and scarring of the
human retina (Bringmann and Wiedemann, 2012). A population of
Müller glia with stem cell characteristics (hMSC) has been identiﬁed in
the adult human retina (Bhatia et al., 2009b; Lawrence et al., 2007).
Upon isolation in vitro these cells become spontaneously immortalized
(Limb et al., 2002) and can be induced to express markers of retinal
ganglion cells or photoreceptor neurons by culture with growth and
diﬀerentiation factors (Jayaram et al., 2014; Singhal et al., 2012). In
addition, Müller glia can be induced to proliferate in situ in human
retinal explants cultured with growth and diﬀerentiation factors (Bhatia
et al., 2009a). Although there is no evidence that Müller glia proliferate
or neurally diﬀerentiate in situ, the observations that they can pro-
liferate indeﬁnitely in vitro and diﬀerentiate into retinal neurons upon
culture with diﬀerentiation factors, suggest that Müller glia may have
the potential to repair the human retina in vivo. However for unknown
developmental reasons, they are prevented from exerting this
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regenerative function.
Various studies have examined the proteome proﬁle of the retina
using experimental disease models (Böhm et al., 2013; Kim et al., 2012;
Ly et al., 2014; Tu et al., 2013), but proteomic investigations of the
gliotic human retina have been limited. Recent studies however, have
identiﬁed 3436 non-redundant proteins in the normal human retina
(Zhang et al., 2015), contributing to the mapping of the human retinal
proteome which may aid investigations into disease mechanisms. Sev-
eral proteomic studies on the characterisation of Müller glia has been
performed on cells isolated from rodent or porcine retina (Grosche
et al., 2015; Hauck et al., 2003; Merl et al., 2012), but investigations
into the proteomic proﬁle of human Müller glia in the context of retinal
gliosis have not been reported. This study has therefore attempted to
examine the contribution of human Müller glia to the proteomic proﬁle
of the gliotic human retina by comparing the protein expression proﬁles
of gliotic and normal human retina with that of Müller glia cell lines in
vitro.
2. Materials and methods
2.1. Tissue acquisition
Retinae from four normal cadaveric donors with prior consent for
research were obtained from Moorﬁelds eye Bank under 24 h post
mortem. Specimens for protein analysis were obtained by excising
sections of normal peripheral retina between 1 and 3mm x 1–5mm
(3–5mm2) to match the size of the retinectomy specimens obtained. Six
peripheral retinectomy specimens (3–5mm2) from eyes undergoing
retinal surgery for treatment of proliferative vitreo-retinopathy (PVR)
(duration of 2–10 weeks) were obtained according to guidelines from
the Local Ethics Committee at Moorﬁelds and the Institute of
Ophthalmology and followed the tenets of the Declaration of Helsinki.
Donors ages ranged from 32 to 83yrs and matched where possible.
Before pooling for the proteomics assays, specimens were washed in
phosphate buﬀered saline (PBS) and frozen at −80 °C until use.
2.2. Cell culture
The immortalized human Müller cell line MIO-M1 (Limb et al.,
2002) was used in this study along with the immortalized Müller cell
preparations 6387 (MIO-M7), 6391(MIO-M4) and 6390 (MIO-M5)
generated in our laboratory. Cells were grown to conﬂuence in 10%
foetal calf serum (FCS, Invitrogen, UK) in DMEM with GlutaMAX
(31966-021; Invitrogen UK) at 37 °C in the presence of 5% CO2.
2.3. Protein isolation and proteomic analysis of human retina and Müller
glial cells
Retinal fragments and Müller cell preparations were washed in PBS
prior to homogenisation with 50 nM Ammonium Bicarbonate
+2%ASB-14 (Sigma Aldrich, UK) pH8.2. Protein content was estimated
using the Bicinchoninic Acid (BCA) protein assay kit (Sigma-Aldrich,
UK).
2.4. 2-Dimensional gel electrophoresis (2D-DIGE) assay
Human retina protein isolated from 4 normal, 5 gliotic specimens,
as well as 4Müller glia cell preparations were combined to create 3
separate pools, each consisting of 150 μg of protein. 2D-DIGE analyses
were performed as previously described (Heywood et al., 2011). Each
protein pool was labelled with a diﬀerent CyDye (600 pmol) as follows:
Control retina was labelled with Cy3; gliotic retina with Cy5 and Müller
glia with Cy2. Samples were then combined and added to Immobiline
DryStrip gels (IPG) and run on an IPG Multiphor II Electrophoresis
System (GE Healthcare, Little Chalfont, U.K.). For the second dimen-
sion, Isoelectric focusing (IEF) strips were re-equilibrated before
resolving samples on an Ettan DALT twelve System separation tank
using 12% acrylamide gels. Gels were ﬁxed and imaged using a Ty-
phoon scanner (Model 8600, GE Healthcare, UK). Spot comparison was
performed using Progenesis Samespots software (Non-Linear Dynamics,
Waters, UK). Gels were silver stained (Heywood et al., 2011) and pro-
tein spots excised, trypsin digested and processed as for mass spectro-
metry.
2.5. Label free proteomics
Similarly, three diﬀerent pools from normal, gliotic human retina
and Müller glia were used for label free proteomics. Freeze-dried
samples (80 μg each) were reconstituted in homogenisation buﬀer
(50 mM AmmoniumBicarb + 2%ASB-14) and run on a 1D gel (BioRad
Mini Protean Precast gels, BioRad, UK) as described previously
(Heywood et al., 2011). Ten gel bands of each sample lane were excised
according to molecular weight and subjected to trypsin digestion and
peptide extraction as previously described (Bennett et al., 2010). Di-
gests were reconstituted in 30 μl of 3%ACN +0.1% Triﬂuoroacetic acid
(TFA) with yeast enolase added as an internal standard and analysed
using a QToF Premier™ mass spectrometer coupled to a NanoAquity
Nano-LC system (Waters Corp, UK).
2.6. Data analysis
Specimens (normal retina, gliotic retina and Müller glia) were as-
sessed for diﬀerentially expressed proteins giving an n number of 1 for
each condition. Therefore, the high cut-oﬀ values of ≥2-fold upregu-
lated or ≤0.5-fold downregulated were chosen to obtain higher con-
ﬁdence when analysing the data.
Proteins were identiﬁed using ProteinLynx Global Server (PLGS) 2.4
(Waters, UK) with a downloaded Uniprot reference proteome for homo
sapiens with porcine trypsin (Accession: P00761) and yeast enolase
(Accession: P00924) added. Results generated were further processed
through Progenesis QI software (Non-linear dynamics, Waters UK).
Only proteins identiﬁed by 2 or more peptides were used in compara-
tive analyses, Supplementary Table 1 contains the list of proteins used
in the analysis. Further analyses of the results were conducted on web-
based platforms including the Panther Classiﬁcation System (http://
www.pantherdb.org/), (Mi et al., 2013) gene ontology classiﬁcation by
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) (Wang et al.,
2013) and IMPaLA (http://impala.molgen.mpg.de/) for pathway ana-
lysis (Kamburov et al., 2011).
Mass spectrometry proteomics data have been deposited in the
ProteomeXchange Consortium database (http://proteomecentral.
proteomexchange.org) via the PRIDE partner repository (Vizcaino
et al., 2013) with the dataset identiﬁer PXD008485.
2.7. Western blot analysis
Cell lysis and western blot analysis was performed as previously
described (Lawrence et al., 2007). Aliquots of cell lysates were resolved
on 4–12% NuPAGE Bis-Tris gels (Invitrogen, U.K.). Proteins were
transferred to PDVF membranes (Semi-dry transfer, Biorad,UK) and
blocked with 5% FBS and 5% skimmed milk powder in TBS. Im-
munodetection was performed using primary antibodies against vi-
mentin (1:250; Santa Cruz), galectin-1 (1:5000; Abcam), and GFAP
(1:2000; DAKO). Protein bands were detected following incubation
with donkey antiserum against rabbit, or mouse IgG coupled to horse-
radish peroxidase (Santa Cruz Biotechnology Inc). Chemiluminescence
was detected using Millipore Luminata detection reagents and resolved
using an x-ray developer.
2.8. Immunohistochemistry
Human tissue samples from normal retina or gliotic PVR retina were
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ﬁxed in 4% PFA for 30mins, cryopreserved in 30% sucrose and em-
bedded in OCT for cryosectioning. For immunostaining, sections were
blocked (TBS + 0.3% triton X 5% donkey serum) for 1 h prior to the
addition of the primary antibody, incubated overnight at 4 ̊ C. Sections
were then washed with TBS and incubated in secondary antibodies
(Alexa ﬂour, 1:500 in TBS + 0.3% triton) for 3 hrss at room tem-
perature in the dark. Slides were then washed in TBS and counter-
stained with a mounting medium containing DAPI (Fluoroshield;
Abcam) before coverslipping.
3. Results
3.1. Proteomic proﬁles of Müller glial cell lines and of normal and gliotic
human retina examined by label free analysis
Analysis of protein expression by label free mass spectrometry
identiﬁed 1527 proteins in Müller glial cell preparations, 1631 proteins
in normal retina and 1074 in gliotic PVR retina. In Müller glial cell
preparations vimentin exhibited the highest abundancy (14% of total
protein), but GFAP only constituted 1.43% of the protein content. Other
proteins highly expressed in Müller glia included histone H4 (6.17%),
actin cytoplasmic 1 (3.56%) and annexin A2 (3.02%) (Fig. 1A). In
normal retina GAPDH was the most abundant protein and constituted
6.06% of the total protein. This was followed by vimentin (5.04%),
alpha enolase (5.02%) and creatine kinase b type (4%) (Fig. 1B). In
gliotic retina, vimentin was the most abundant protein, constituting
13.4% of total protein, followed by GFAP (7.4%), histone H4 (5.58%)
and alpha enolase (5.54%) (Fig. 1C). Supplementary Table 1 shows the
full list of identiﬁed proteins in each group which were used for ana-
lysis.
3.2. Diﬀerences in protein expression between normal and gliotic PVR retina
and Müller glial proﬁle
As identiﬁed by label free mass spectrometry and based on a> 2-
fold increase in expression, 28 proteins were upregulated in the gliotic
retina as compared to normal retina. Quinone oxidoreductase exhibited
the highest fold change (9.22-fold) followed by CD166 (8.2-fold) and
protein canopy homolog 2 (6.83-fold). A large proportion of upregu-
lated proteins are involved in cytoskeletal regulation and included the
ﬁlament proteins ezrin, glial ﬁbrillary acidic protein, desmin and vi-
mentin. Nucleic acid binding proteins were also upregulated in gliotic
retina and included histones, ribosomal proteins and poly-ubiquitin
(Table 1). Interestingly, all the proteins found upregulated in the gliotic
retina, were also present in the Müller cell preparation. These have
been highlighted in Table 1, showing the associated ranked abundan-
cies within the Müller cell preparation. Of the 30 most abundant pro-
teins identiﬁed by mass spectrometry in Müller glial cell lysates, vi-
mentin showed the highest abundance, followed by histone H4 and
actin cytoplasmic 1 (Fig. 2). Four of the 30 most abundant proteins
observed in Müller cell preparations were found highly upregulated in
the gliotic retina as compared to normal retina. These included vi-
mentin, GFAP, heat shock protein 90α and polyubiquitin C (Fig. 2).
Well known Müller glia markers were also predominant in Müller
cell preparations and included glutamine synthetase, retinaldehyde
binding protein 1 and CD44-antigen. Of these, both glutamine synthe-
tase and retinaldehyde binding protein 1 were downregulated in the
gliotic retina as compared to normal retina. Several proteins present in
Müller cell lysates have not been previously identiﬁed in Müller glia
and included prelamin A/C, elongation factor 1, and serpin H1. Further
details can be found in Supplementary Table 2.
Based on<0.5-fold decrease in expression, 196 proteins were
downregulated in the gliotic retina as compared to normal retina.
Mitochondrial 2 oxoglutarate malate carrier protein showed the
greatest decrease in the gliotic retina (0.005-fold), followed by Tubulin
alpha 8 chain (0.01-fold) and reticulon 4 (0.1-fold). The majority of
downregulated proteins identiﬁed are involved in nucleic acid binding
including ribosomal related proteins (Table 2).
3.3. Comparative analysis of protein expression between Müller glia and
normal and gliotic PVR retina as examined by 2D-DIGE
Approximately 200 protein spots were detected in the 2D-DIGE
analysis. Based on a> 2-fold increase in intensity, 8 spots showed>2-
fold upregulation in the gliotic as compared to normal retina, whilst 23
protein spots showed a< 0.5-fold decrease. In addition, all proteins
observed diﬀerentially expressed were present in the Müller cell lysates
(Fig. 3A and B). Proteins from 14 representative gel spots were ex-
tracted and digested prior to mass spectrometry to identify individual
proteins. For each spot, the protein with the highest peptide count was
considered the protein of interest. Proteins showing upregulation in the
gliotic retina as compared to normal retina supported the current mass
spectrometry observations that GFAP, vimentin and aminopeptidase are
highly upregulated in during gliosis. Proteins identiﬁed to be down-
regulated in the gliotic retina as compared to normal retina by 2D-DIGE
analysis included alpha enolase, N(G),N(G)-dimethyl arginine di-
methylaminohydrolase-1, s-arrestin, GAPDH, and carbonic anhydrase 2
(Table 3).
3.4. Gene ontology and pathway classiﬁcation and enrichment analysis of
diﬀerentially expressed proteins in the retina
Proteins upregulated in gliotic retina compared with normal retina
were subject to gene ontology (GO) enrichment analysis to identify key
areas of interest. Proteins grouped according to the GO term ‘biological
processes’ revealed an over-representation associated with the inter-
mediate ﬁlament cytoskeleton, astrocyte development, glial cell dif-
ferentiation and negative regulation of neuron projection development
(Fig. 4A) and included GFAP, vimentin and galectin 1. Similarly, en-
richment analysis of upregulated proteins classiﬁed according to mo-
lecular function, showed structural constituents of the cytoskeleton
signiﬁcantly enriched in the gliotic retina (Fig. 4B) and included GFAP,
vimentin, keratin and desmin. Other protein groups classiﬁed by mo-
lecular function found enriched, although not statistically signiﬁcant,
included iron-ion binding, NAD binding and actin binding proteins
(Fig. 4B). Proteins upregulated in the gliotic retina as compared to
normal retina were subject to IMPaLA pathway analysis. (The top 12
signiﬁcantly over-represented pathways are shown in Supplementary
Table 3). The Liver Kinase B1- also known as Serine/Threonine Kinase
11 - STK11 (LKB1) signalling was the pathway most signiﬁcantly re-
presented within the group, and included the proteins HSP90aa1, ezrin,
and 14.3.3δ. Other pathways highly represented included cellular re-
sponses to stress, regulation of serine/threonine-protein kinase 13 ac-
tivity, also known as polo-like kinase 1 (PLK-1), G2/M transition and
apoptosis (Fig. 4C).
Of the proteins downregulated in the gliotic retina, classiﬁcation
according to biological processes revealed an over-representation of
protein groups associated with bacterial signal recognition particle
(SRP)-dependent co-translational protein targeting the membrane,
mRNA catabolic processes, and translational termination (Fig. 5A).
Enrichment analysis for downregulated proteins classiﬁed according to
molecular function showed that GTPase activity, RNA binding, nu-
cleotide binding, and structural constituents of the ribosome were also
over-represented (Fig. 5B). Pathway analysis was also conducted for
proteins shown to be downregulated in the gliotic retina as compared to
normal retina. (The top 12 most signiﬁcantly downregulated pathways
are shown in Supplementary Table 4). Eukaryotic translation elonga-
tion was most signiﬁcantly represented within the group and included
mainly ribosomal related proteins. Other pathways highly represented
included eukaryotic translation termination, peptide chain elongation
and nonsense mediated decay independent of the exon junction com-
plex (Fig. 5C).
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3.5. Validation of retinal proteomic ﬁndings and localization of identiﬁed
key proteins in Müller glia
To validate our proteomics results we conducted western blot and
immunoﬂuorescence analyses. Using frozen sections of normal human
retina (cadaveric) and gliotic specimens (PVR), we analysed the ex-
pression of the proteins GFAP, vimentin and galectin-1. Although the
lamination of the gliotic retina examined was well preserved in the
specimens examined, the overall morphological appearance is more
irregular than that of the normal retina (Fig. 6A). Immunostaining of
these specimens showed that Vimentin and GFAP was conﬁned to the
Müller glia end-feet region (nerve ﬁbre layer; white arrows) in the
normal retina. In comparison, Vimentin and GFAP immunostaining of
PVR retina showed a widespread distribution of these proteins in Müller
glia throughout the whole retinal section, this is one of the major
characteristics of retinal gliosis (Fig. 6A). Immunostaining of normal
retina for Galectin-1 was observed associated to Müller glia, more
predominantly in the Müller end foot region, and spanning across all
the layers of the retina. However, a more intense and widespread
staining for this molecule was observed in Müller glia throughout the
whole PVR retina (Fig. 6A). Similarly, western blot analysis of protein
lysates from normal and gliotic retina showed an increased abundance
of Vimentin, GFAP and Galectin-1 in the gliotic retina when compared
with the normal retina (Fig. 6B).
Fig. 1. Abundance of proteins as identiﬁed by label free mass spectrometry analysis in normal retina, gliotic retina and Müller glia. For clarity only proteins
with the highest abundance are labelled. (A) Pie chart shows protein abundance represented as percentage of total protein identiﬁed in a pool of Müller glial cell
lysate. (B) Pie chart shows protein abundance represented as percentage of total protein identiﬁed in a pool of 4 normal retinae. (C) Pie chart shows protein
abundance represented as percentage of total protein identiﬁed in a pool of 5 gliotic retinae.
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4. Discussion
This study compared the protein expression proﬁle of Müller glia
with that of normal and gliotic PVR human retina and identiﬁed
changes in cytoskeletal related proteins, extracellular matrix proteins
and ribosomal proteins that occur during retinal gliosis. It would be
important to analyse the proteome of Müller glia isolated from PVR
gliotic retina with cells isolated from normal retina. However, in our
laboratory, attempts to isolate Müller glia from PVR gliotic retina have
been unsuccessful and we have been unable to obtain a stable culture of
these cells despite many attempts (unpublished data). We hypothesise
that this may be due to the gliotic nature of the tissue and the associated
Table 1
Proteins upregulated> 2-fold in gliotic human retina compared to normal retina. Table shows the proteins found upregulated>2-fold in the gliotic retina as
compared to normal retina. They have been grouped according to their major functions for clarity. Ranked abundancies for each protein found in the Müller cell
preparation are listed (Low numbers indicate higher abundancy, e.g. 1= highest abundant protein in the Müller cell preparation).
Protein Class Upregulated Ranked Abundance in Müller preparation
Protein Accession No. Peptides Fold change
Cell adhesion molecule CD166 antigen Q13740 3 8.20 274
Galectin 1 P09382 25 2.03 56
Chaperone Heat shock protein HSP90 alpha P07900 76 2.0 23
Heat shock 70 kDa protein 1 P34931 32 6.70 396
14 3 3 protein sigma P31947 21 4.31 216
Structural molecule activity Ezrin P15311 20 5.25 280
Glial ﬁbrillary acidic protein P14136 217 4.50 15
Desmin P17661 56 4.84 154
Synapsin 1 P17600 2 5.39 369
Keratin type 1 cytoskeletal 16 P08779 18 3.37 358
Tubulin alpha 1A chain Q71U36 199 2.64 86
Vimentin P08670 432 2.53 1
Proﬁlin 1 P07737 21 2.01 36
Membrane traﬃcking protein Synapsin 1 P17600 2 5.39 369
Nucleic acid binding Histone H2B type 1 P23527 143 3.80 289
Small nuclear ribonucleoprotein SM D3 P62318 4 2.83 178
Polyubiquitin 3 P0CG48 37 2.06 28
40s ribosomal protein s20 P60866 2 2.32 272
60s ribosomal protein L36 Q9Y3U8 5 3.90 53
Histone H1 3 P16402 23 2.01 81
Signalling molecule Galectin 1 P09382 25 2.02 56
Tenascin C P24821 2 2.54 188
Oxioreductase Procollagen lysine 2 oxoglutarate 5 dioxygenase 2 O00469 6 2.31 158
D3 phosphoglycerate dehydrogenase O43175 3 2.13 375
Quinone oxidoreductase Q08257 4 9.22 75
MISC Translocon associated protein subunit delta P51571 4 2.17 256
Protein canopy homolog 2 Q9Y2B0 2 6.83 354
Fig. 2. Proteins upregulated in the
gliotic retina are among the 30 most
abundant proteins expressed by
Muller glia. Venn diagram shows the
proteins upregulated in the gliotic
human retina (yellow area) and the 30
most abundant proteins in the Müller
glia cell preparation (blue area) and the
common proteins to both groups (green
area). (For interpretation of the refer-
ences to colour in this ﬁgure legend, the
reader is referred to the Web version of
this article.)
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Müller glial changes that occur during gliosis (Bringmann et al., 2009).
For the current study, we therefore sought samples of PVR gliotic retina
to compare these with normal retina and established human Müller
glial cell lines isolated from normal retina. The results showed im-
portant variations in key proteins expressed in Müller glia and normal
and gliotic retina that highlight a potential signiﬁcance of these mole-
cules during retina degeneration.
Many cytoskeletal proteins, including ezrin and desmin, which are
highly expressed by established human Müller glial cell lines, although
not classiﬁed in the top 30 proteins, were found> 2-fold upregulated in
the gliotic retina. Upregulation of intermediate ﬁlament proteins, in-
cluding GFAP and vimentin are generally accepted as indicators of
retinal stress and Müller glial cell reactivity during retinal gliosis
(Grosche et al., 1995; Lewis and Fisher, 2003), and are further sup-
ported by observations in vimentin and GFAP deﬁcient mice, in which
decreased photoreceptor degeneration and attenuated glial reactions
are observed (Nakazawa et al., 2007). Ezrin, a peripheral membrane
protein which aids in the organisation of cell morphology (Vaheri et al.,
1997), has been found to be upregulated in a rabbit model of PVR
(Zhou et al., 2012), suggesting that this protein may also be associated
with human retinal gliosis. In zebraﬁsh, Müller glia expression of GFAP
is usually upregulated after retinal damage (Thomas et al., 2015), but
upon regeneration GFAP expression is downregulated (Thummel et al.,
2008). This suggests that GFAP may be more intricately regulated in
Müller glia than ﬁrst thought and that its expression may be potentially
associated to the non-regenerative ability of these cells. These ﬁndings
support previous observations of GFAP upregulation in the human
gliotic retina, and highlight the importance of Müller cell structural
changes in retinal remodelling during gliosis. These observations also
indicate the importance to investigate the regulation of intermediate
Table 2
Proteins downregulated in the gliotic human retina compared to normal retina. Table shows the 50 proteins found to be downregulated<0.5-fold in the
gliotic retina as compared to normal retina. They have been grouped according to their major functions for clarity.
Protein Class Downregulated
Protein Accession No.Peptides Fold change
Chaperone Putative Heat shock protein 90 beta 2 Q58FF8 35 0.04
Structural molecule activity Keratin type II cuticular Hb3 P78385 11 0.06
Tubulin alpha 8 chain Q9NY65 83 0.01
Keratin type II cuticular Hb2 Q9NSB4 3 0.08
Neuroﬁlament medium polypeptide P07197 16 0.06
Tropomyosin alpha 1 chain P09493 18 0.07
Membrane traﬃcking protein Reticulon 4 Q9NQC3 2 0.01
Endoplasmic reticulum resident protein 29 P30040 5 0.15
Coatomer subunit alpha P53621 4 0.12
Nucleic acid binding Matrin 3 P43243 3 0.09
Proliferating cell nuclear antigen P12004 2 0.04
60S ribosomal protein L24 P83731 3 0.04
Poly rC binding protein 3 P57721 7 0.03
Poly ADP ribose polymerase 1 P09874 2 0.02
40S ribosomal protein S11 P62280 7 0.11
Transcriptional activator protein Pur alpha Q00577 2 0.08
ADP ATP translocase 1 P12235 46 0.07
40S ribosomal protein S4 X P62701 6 0.02
60S ribosomal protein L13a P40429 2 0.13
40S ribosomal protein S9 P46781 8 0.09
Core histone macro H2A 1 O75367 13 0.13
60S ribosomal protein L13 P26373 4 0.02
Mitochondrial 2 oxoglutarate malate carrier protein Q02978 6 0.005
40S ribosomal protein S26 P62854 3 0.12
60s Ribosomal protein L14 P50914 6 0.11
Non histone chromosoaml protein HMG P05114 5 0.14
40S ribosomal protein S23 P62266 2 0.13
Polyadenylate binding protein 1 Q4VXU2 2 0.13
ATP synthase subunit gamma mitochondrial P36542 9 0.14
Guanine nucleotide binding protein GIGSGT subunit beta 1 P62873 29 1.13
Adenylate kinase isoenzyme 1 P00568 2 0.14
Signalling molecule Membrane associated progesterone receptor component 1 O00264 4 0.12
Transferase Hypoxanthine guanine phosphoribosyltransferase P00492 4 0.03
Creatine kinase U type mitochondrial P12532 4 0.07
ATP citrate synthase P53396 4 0.12
Guanylate kinase Q16774 4 0.09
Oxioreductase Peroxiredoxin 4 Q13162 10 0.06
NADH cytochrome b5 reductase 3 P00387 6 0.08
Estradiol 17 beta dehydrogenase 12 Q53GQ0 2 0.05
Glycerol 3 phosphate dehydrogenase mitochondrial P43304 3 0.07
Isocitrate dehydrogenase NAD subunit alpha P50213 4 0.14
Procollagen lysine 2 oxoglutarate 5 dioxygenase 3 O60568 7 0.15
Detoxiﬁcation Glutathione S-transferase Mu 2 P28161 4 0.02
Enzymes/modulators Interleukin enhancer binding factor 3 Q129606 5 0.14
Inorganic pyrophosphatase Q15181 3 0.02
Poly rC binding protein 2 Q15366 8 0.14
Transcription factor Cullin associated NEDD8 dissociated protein 1 Q86VP6 3 0.10
Transcriptional activator protein Pur alpha Q00577 2 0.08
MISC Proteasome subunit alpha type 7 O14818 2 0.06
Prohibitin P35232 8 0.13
Thioredoxin domain containing protein 5 Q8NBS9 2 0.13
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ﬁlament changes in human Müller glia that lead to these cells entering a
gliotic state in favour of a progenitor-like state.
It is documented that extracellular matrix remodelling and gliosis
occur in retinal diseases such as glaucoma (Wallace et al., 2014; Yan
et al., 2000), diabetic retinopathy (Ioachim et al., 2005), PVR (Kon
et al., 1998) and AMD (Nita et al., 2014). The ﬁndings that factors such
as Tenascin C, PLOD2, CD166 and galectin1 are highly upregulated in
gliotic retina, are therefore supported by these studies. Tenascin C is a
glycoprotein involved in tissue remodelling and is known to support
growth and diﬀerentiation. It is expressed in the ECM during devel-
opment and injury (Jones and Jones, 2000) and it is found upregulated
during diabetic retinopathy (Spirin et al., 1999). It has been postulated
that Tenascin contributes to mechanical stiﬀness of the retina (Davis
et al., 2012) and it is often co-expressed with matrix metalloproteinases
(MMPs) (Jian et al., 2001), suggesting its importance in the deposition
of the extracellular matrix during reactive gliosis. Upregulation of Te-
nascin C has also been linked to growth factors and cytokines such as
TGFβ1, interleukin 1 and TNFα (Rettig et al., 1994), which have been
associated with retinal degenerative disorders (Eastlake et al., 2016),
suggesting that Tenascin C may contribute to gliosis. Galectin-1, a beta-
galactoside-binding protein that plays an important role in cell adhe-
sion and proliferation (Camby et al., 2006), has been previously im-
plicated in retinal disease. Neutralising galectin-1 activity in rat eyes is
reported to increase susceptibility to retinal detachment due to weak
RPE and neural retinal adhesion (Uehara et al., 2001). Although up-
regulation of this protein could promote neural retina-RPE integrity, it
may also induce retinal traction that perpetuates retinal detachment in
PVR. Since Müller glia was observed to highly express Galectin 1 within
the retina (Fig. 6), it is possible that these cells are the main source of
this protein in the retina and studies are needed to determine the role of
this protein during gliosis. Although the cell adhesion molecule CD166
(also known as ALCAM) is expressed by retinal ganglion cell axons
during retinal development (Avci et al., 2004; Diekmann and Stuermer,
2009), its role during retinal degeneration has yet to be explored and
constitutes a valid target for future investigations.
The observations that retinal speciﬁc proteins such as rhodopsin, s-
arrestin, recoverin, retinaldehyde binding protein, Thy1 and rod cGMP,
were severely downregulated in the gliotic retina, may reﬂect the
neural cell death observed during gliosis. The ﬁndings that re-
tinoschisin, an extracellular protein that plays a crucial role in the
cellular organisation of the retina, and glutamine synthetase, an en-
zyme that plays a key metabolic role within the retina, were also
markedly decreased in the gliotic retina may indicate key metabolic
changes occurring in Müller glia during gliosis (Grosche et al., 1995;
Lewis et al., 1989; Reid and Farber, 2005). Since downregulation of
reticulon 4 (Neurite outgrowth inhibitor/Nogo) enhances neuronal cell
Fig. 3. 2D-DIGE gel analysis of normal and gliotic human retina. (A)
Fluorescent gel image showing labelled proteins from a pool of 4Müller glial
cell preparations (Cy2= green), 5 gliotic retinal specimens (Cy5=Blue) and 4
normal retinae specimens (Cy3=Red). (B) Representative 2D DIGE gel of a
pool of 4 normal retina. Numbered protein spots are those shown to be dif-
ferentially expressed between the gliotic and human retina by more than 2-fold.
Table 3 shows the protein identiﬁcation of the numbered spots shown in this
Figure. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the Web version of this article.)
Table 3
Diﬀerentially expressed proteins in the retina as identiﬁed by 2D DIGE. Table shows the identiﬁcation of protein spots highlighted in Fig. 2 following mass
spectral analysis. Fold diﬀerences in expression between normal retina (N), and gliotic retina (G) are shown.
Spot Uniprot ID Accession Peptide count Protein name Fold diﬀerence
G/N
Spot 788 AMPL_HUMAN P28838 5 Cytosol aminopeptidase 2.06
Spot 1567 GFAP_HUMAN P14136 38 Glial ﬁbrillary acidic protein 2.05
Spot 1568 ENOA_HUMAN P06733 29 Alpha-enolase 0.45
Spot 891 ENOA_HUMAN P06733 25 Alpha-enolase 0.43
Spot 1561 DDAH1_HUMAN O94760 16 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 0.45
Spot 1603 CAH2_HUMAN P00918 15 Carbonic anhydrase 2 0.43
Spot 820 ARRS_HUMAN P10523 11 S-arrestin 0.27
Spot 1553 ARRS_HUMAN P10523 3 S-arrestin 0.26
Spot 1080 DDAH1_HUMAN O94760 4 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 0.49
Spot 831 ARRS_HUMAN P10523 3 S-arrestin 0.38
Spot 1125 G3P_HUMAN P04406 28 GAPDH 0.32
Spot 1005 VIME_HUMAN P08670 44 Vimentin 2.67
Spot 759 PDIA1_HUMAN P07237 17 Protein disulphide-isomerase 1.30
Spot 943 VIME_HUMAN P08670 66 Vimentin 2.13
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growth and survival in the mouse retina (Kim et al., 2003), the present
ﬁndings that Nogo was downregulated in the gliotic retina may indicate
the existence of endogenous mechanisms triggered during gliosis to
protect neurons from further damage. Although the present study does
not provide evidence for the cells involved in the downregulation of
Nogo, or the mechanisms underlying its decreased expression in the
gliotic retina, it justiﬁes further studies into the mechanisms that reg-
ulate the expression of these factors in the developed retina.
Pathway analysis studies showed that LKB1 signalling was posi-
tively regulated in the gliotic retina as compared to normal retina. LKB1
signalling is involved in the control of cell growth and metabolism by
phosphorylation of the AMPK metabolic sensor (Lizcano et al., 2004),
whilst HSP90AA1 bind and stabilise LKB1, possibly enhancing LKB1
signalling and cell growth inhibition (Gaude et al., 2012). Increased
LKB1 signalling could lead to cell growth arrest and its upregulation
during gliosis may reﬂect the damage observed. Several pathways in-
volved in ribosomal processes were negatively regulated in the gliotic
retina as compared to normal retina, suggesting that downregulation of
the ribosomal subunits 40s and 60s may indicate a reduction in mRNA
processing and protein translation during gliosis. In addition, loss of
ribosome biogenesis is associated with ribosome stress, triggering ac-
tivation of the p53 apoptotic pathway (Wang et al., 2015), therefore the
loss of ribosome function could be ascribed to cell death occurring
during gliosis and investigations into the activation of these pathways
in Müller glia may provide important information on how these cells
are aﬀected during gliosis.
Fig. 4. Gene ontology and pathway analysis of proteins identiﬁed to be
upregulated in the gliotic retina as compared to normal retina. Figures
have been simpliﬁed from WebGestalt GO, and IMPALA analysis results to show
the classiﬁcation and enrichment analysis of proteins found to be 2-fold upre-
gulated in the gliotic retina as compared to normal retina. Gene ontology
classiﬁcations highlighted in black represent statistically signiﬁcant enriched
gene ontology categories (P < 0.05) (Benjamin and Hochberg false discovery
rate correction), whereas those highlighted grey indicate those which are of the
top 10 non-signiﬁcantly enriched categories where P > 0.05. Diagram shows
GO categories and proteins assigned to those categories for (A) Biological
processes (B) Molecular function. Similarly pathway analysis (C) shows the
most signiﬁcantly enriched signalling pathways of proteins 2-fold upregulated
in the gliotic retina.
Fig. 5. Gene ontology analysis of proteins identiﬁed to be downregulated
in the gliotic retina as compared to normal retina. Figures have been sim-
pliﬁed from WebGestalt GO results to show the classiﬁcation and enrichment
analysis of proteins found to be < 0.5-fold downregulated in the gliotic retina
as compared to normal retina. Gene ontology classiﬁcations highlighted in
black represent statistically signiﬁcant enriched gene ontology categories
(P < 0.05) (Benjamin and Hochberg false discovery rate correction). Diagram
shows GO categories and proteins assigned to those categories for (A) Biological
processes (B) Molecular function. Similarly, pathway analysis (C) shows the
most signiﬁcantly enriched pathways of the proteins which were 2-fold
downregulated in the gliotic retina.
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Müller glia markers identiﬁed in Müller cell lysates included GFAP,
vimentin, glutamine synthetase, CD44 antigen and retinaldehyde
binding protein 1 (CRALBP). It is reported that retinal Müller glia lose
these in vivo features and undergo senescence with passaging in culture
(Sarthy et al., 1998). Porcine Müller glia become ﬁbroblastic after three
days in culture and show upregulation of proteins associated with cy-
toskeleton, motility and proliferation, while downregulating those in-
volved in transmitter recycling, glycolysis and detoxiﬁcation (Hauck
et al., 2003). In contrast, Müller glia that exhibit stem cell properties
maintain their characteristic morphology (Limb et al., 2002) and al-
though they may undergo adaptation changes to culture environments,
the present results showed that immortalized Müller cell lines express
speciﬁc markers associated with Müller glia at high levels. This corre-
lates with previous observations that Müller stem cells continue to ex-
press Müller glia markers after 100 passages (Limb et al., 2002). We
also identiﬁed proteins that have not previously reported to be ex-
pressed by Müller glia, including prelamin A/C, elongation factor 1, and
serpin H1, for which it will be important to assess the functions of these
factors during retinal gliosis. Additionally, markers highly expressed by
Müller glia, including vimentin, GFAP, HSP90AA1 and poly-ubiquitin
C, were also found>2-fold upregulated in the gliotic retina. Ubiqui-
tination is one of the most important post-translational modiﬁcations of
proteins and is involved in various cellular activities, such as protein
degradation, apoptosis, DNA transcription and repair, cell division,
neural degeneration and stress responses amongst others (Inobe and
Nozaki, 2016). It is possible that the main source of poly-ubiquitin C
found in the gliotic retina is Müller glia, thus highlighting the con-
tribution of these cells to the gliotic changes that occur in the retina
after disease or injury. Controlling ubiquitination may therefore
constitute an approach to control gliosis and merits further investiga-
tions.
The issue of missing data values in label free proteomics analysis via
mass spectrometry is widely discussed in the literature and considered a
major concern (Lazar et al., 2016). Analysis of our dataset was pro-
cessed through Progenesis software, which has been reported to gen-
erate consistent accurate results and very few missing data values
(Valikangas et al., 2017). Although this software does not give a
‘missing data rate’ it does however produce some hits which are pre-
sented as having zero abundance which could be considered missing
data and therefore these were excluded from our study.
In the present study it is possible that factors expressed by Müller
glia may be under-represented in the retinal samples due to the pre-
sence of other retinal cell types. Nevertheless, variations in key proteins
expressed in Müller glia and normal and gliotic retina highlight the
importance of these molecules in retina degeneration. It also paves the
way for further investigations into mechanisms that control the ex-
pression of gliosis associated proteins by Müller glia and their potential
role in the prevention or promotion of endogenous regeneration of the
adult mammalian retina.
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Fig. 6. Validation of proteomic proﬁle
(A) Confocal images showing the expression
of vimentin, GFAP and Galectin 1 by normal
and gliotic human retina. As compared with
normal retina, the gliotic retina showed a
widespread and more intense staining for all
three proteins, which was localized to
Müller glia. White arrows show Müller end-
feet; RGC= retinal ganglion cell layer;
INL= inner nuclear layer; ONL=outer
nuclear layer. Sections counterstained with
DAPI to visualize retinal lamination. Scale
bars: 20 μm (B) Western blot gels and cor-
responding histograms show an increase in
vimentin, GFAP and Galectin-1 in the gliotic
retinal specimens.
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Appendix A. Supplementary data
Supplementary data related to this article can be found at https://
doi.org/10.1016/j.exer.2018.08.016.
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